Literature DB >> 29672417

Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard?

Matthew Hg Katz1, Michael P Kim, Ching-Wei Tzeng, Jeffrey E Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29672417      PMCID： PMC6037551          DOI： 10.1097/SLA.0000000000002783

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  15 in total

1.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 2.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

3.  Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alok A Khorana; Pamela B Mangu; Jordan Berlin; Anitra Engebretson; Theodore S Hong; Anirban Maitra; Supriya G Mohile; Matthew Mumber; Richard Schulick; Marc Shapiro; Susan Urba; Herbert J Zeh; Matthew H G Katz
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

4.  Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Margaret A Tempero; Mokenge P Malafa; Mahmoud Al-Hawary; Horacio Asbun; Andrew Bain; Stephen W Behrman; Al B Benson; Ellen Binder; Dana B Cardin; Charles Cha; E Gabriela Chiorean; Vincent Chung; Brian Czito; Mary Dillhoff; Efrat Dotan; Cristina R Ferrone; Jeffrey Hardacre; William G Hawkins; Joseph Herman; Andrew H Ko; Srinadh Komanduri; Albert Koong; Noelle LoConte; Andrew M Lowy; Cassadie Moravek; Eric K Nakakura; Eileen M O'Reilly; Jorge Obando; Sushanth Reddy; Courtney Scaife; Sarah Thayer; Colin D Weekes; Robert A Wolff; Brian M Wolpin; Jennifer Burns; Susan Darlow
Journal:  J Natl Compr Canc Netw       Date:  2017-08       Impact factor: 11.908

5.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Authors:  Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

6.  International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.

Authors:  Shuji Isaji; Shugo Mizuno; John A Windsor; Claudio Bassi; Carlos Fernández-Del Castillo; Thilo Hackert; Aoi Hayasaki; Matthew H G Katz; Sun-Whe Kim; Masashi Kishiwada; Hirohisa Kitagawa; Christoph W Michalski; Christopher L Wolfgang
Journal:  Pancreatology       Date:  2017-11-22       Impact factor: 3.996

7.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

8.  Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Authors:  Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

9.  Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.

Authors:  Henriette Golcher; Thomas B Brunner; Helmut Witzigmann; Lukas Marti; Wolf-Otto Bechstein; Christiane Bruns; Henry Jungnickel; Stefan Schreiber; Gerhard G Grabenbauer; Thomas Meyer; Susanne Merkel; Rainer Fietkau; Werner Hohenberger
Journal:  Strahlenther Onkol       Date:  2014-09-25       Impact factor: 3.621

10.  Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.

Authors:  Matthew H G Katz; Fang-Shu Ou; Joseph M Herman; Syed A Ahmad; Brian Wolpin; Robert Marsh; Spencer Behr; Qian Shi; Michael Chuong; Lawrence H Schwartz; Wendy Frankel; Eric Collisson; Eugene J Koay; JoLeen M Hubbard; James L Leenstra; Jeffrey Meyerhardt; Eileen O'Reilly
Journal:  BMC Cancer       Date:  2017-07-27       Impact factor: 4.430
View more
  1 in total

1.  Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival.

Authors:  Anne E O'Shea; Phillip M Kemp Bohan; Elizabeth L Carpenter; Patrick M McCarthy; Alexandra M Adams; Robert C Chick; Julia O Bader; Robert W Krell; George E Peoples; Guy T Clifton; Daniel W Nelson; Timothy J Vreeland
Journal:  Ann Surg Oncol       Date:  2022-05-18       Impact factor: 4.339
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.